Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (19201)	1/6/2000 3:35:00 PM
From: elcasmirb	Respond to of 150070

Lorus Therapeutics Reports Results of International Scientific Study Business Editors TORONTO--(BUSINESS WIRE)--Dec. 20, 1999-- Lorus Therapeutics I(TSE:LOR.) (ME:LOR.) (OTC Bulletin Board:LORFF) - Reported in Gene - An International Journal on Genes and Genomes - Lorus Therapeutics Inc. ("Lorus") announced today that it has published a report in the scientific journal, entitled Gene (Volume 238), which describes a unique role for the ribonucleotide reductase R2 gene in the development and growth of tumors. The report was a collaboration of efforts between Lorus and scientists at the National Institutes of Health in the United States and the University of Manitoba in Canada. "By understanding that an abnormal elevation in the R2 component leads to an increase in the malignant properties of tumor cells, we were able to develop a series of specific anticancer drugs that could potentially be used to treat a wide variety of cancers. The first two drugs to come from this research are GTI 2040 and GTI 2501," said Dr. Jim Wright, president and chief scientific officer at Lorus. "Understanding the role of the R2 component of the ribonucleotide reductase gene in cancer progression is extremely important because it provides us with additional information on possible new targets for drug design and treatment strategies." Lorus recently announced an important step forward with the stamp of approval from the U.S. Food and Drug Administration ("FDA") for the company's Investigational New Drug ("IND") application to begin clinical trials of the anti-cancer drug, GTI 2040. The clinical trials will take place under the direction of Dr. Richard Schilsky of the Chicago Cancer Research Center. Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical development and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange and the Montreal Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Lorus Therapeutics Inc.'s press releases are available through the company's Internet site: www.lorusthera.com.